| Date Filed | Type | Description |
| 08/11/2023 |
S-8
| Form S-8 - Securities to be offered to employees in employee benefit plans: |
| 08/10/2023 |
8-K
| Quarterly results |
| 08/10/2023 |
10-Q
| Quarterly Report for the period ended June 30, 2023 |
| 05/26/2023 |
SC 13D/A
| AGENUS INC reports a 62.5% stake in MINK THERAPEUTICS, INC. |
| 05/11/2023 |
10-Q
| Quarterly Report for the period ended March 31, 2023 |
| 05/11/2023 |
8-K
| Quarterly results |
| 05/03/2023 |
SC 13D/A
| Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend] |
| 03/24/2023 |
10-K
| Annual Report for the period ended December 31, 2022 |
| 03/21/2023 |
8-K
| Quarterly results|
Docs:
|
"MiNK Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results NEW YORK, March 21, 2023 -- MiNK Therapeutics, Inc. , a clinical-stage biopharmaceutical company pioneering the discovery, development, and commercialization of allogeneic, off-the-shelf, invariant natural killer T cell therapies to treat cancer and other immune-mediated diseases, today reported financial results for the fourth quarter and full year 2022. “2022 has been an important year for MiNK, with significant progress across our clinical and preclinical programs in iNKT cell therapy, bolstered by the expansion of our in-house manufacturing capabilities," stated Dr. Jennifer Buell, President and Chief Executive Officer of MiNK. "Our advancements have solidified MiNK's position as a leader in the iNKT cell the..." |
|
| 11/09/2022 |
EFFECT
| Form EFFECT - Notice of Effectiveness: |
| 11/03/2022 |
S-3
| Form S-3 - Registration statement under Securities Act of 1933: |
| 11/03/2022 |
8-K
| Quarterly results |
| 11/03/2022 |
10-Q
| Quarterly Report for the period ended September 30, 2022 |
| 08/15/2022 |
10-Q
| Quarterly Report for the period ended June 30, 2022 |
| 08/09/2022 |
8-K
| Quarterly results |
| 08/05/2022 |
8-K
| Quarterly results |
| 07/15/2022 |
S-8
| Form S-8 - Securities to be offered to employees in employee benefit plans: |
| 06/14/2022 |
8-K
| Quarterly results |
| 05/13/2022 |
10-Q
| Quarterly Report for the period ended March 31, 2022 |
| 05/10/2022 |
8-K
| Quarterly results |
| 04/29/2022 |
DEF 14A
| Form DEF 14A - Other definitive proxy statements: |
| 03/18/2022 |
10-K
| Annual Report for the period ended December 31, 2021 |
| 03/08/2022 |
8-K
| Quarterly results |
| 02/14/2022 |
SC 13G
| ARMEN GARO H reports a 7.8% stake in MiNK Therapeutics, Inc. |
| 02/14/2022 |
5
| ARMEN GARO H (Director) has filed a Form 5 on MiNK Therapeutics, Inc. |
| 01/06/2022 |
8-K
| Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements... |
| 11/29/2021 |
10-Q
| Quarterly Report for the period ended September 30, 2021 |
| 10/28/2021 |
SC 13D
| AGENUS INC reports a 79.8% stake in MINK THERAPEUTICS, INC. |
| 10/20/2021 |
8-K
| Quarterly results |
| 10/15/2021 |
424B4
| Form 424B4 - Prospectus [Rule 424(b)(4)]: |
| 10/15/2021 |
EFFECT
| Form EFFECT - Notice of Effectiveness: |
| 10/14/2021 |
FWP
| Form FWP - Filing under Securities Act Rules 163/433 of free writing prospectuses: |
| 10/14/2021 |
CERT
| Form CERT - Certification by an exchange approving securities for listing: |
| 10/13/2021 |
8-A12B
| Form 8-A12B - Registration of securities [Section 12(b)]: |
|